More than 700 lawsuits have been filed against the manufacturers of Zantac and ranitidine by patients diagnosed with cancer, according to court documents that were recently filed by lawyers involved in the litigation. The two heartburn drugs were recalled by the FDA in 2020 after researchers found that they were contaminated with a chemical linked to an increased cancer risk. (more…)
Dozens of patients who developed cancer after using the heartburn drugs Zantac or ranitidine will have their cases heard in California state court, a Florida federal judge has ruled. The lawsuits were filed by 41 Zantac or ranitidine users against pharmaceutical companies that manufactured the heartburn drugs or pharmacy chains where the drugs were sold. (more…)
The heartburn drug Zantac and its generic equivalent, ranitidine, were recalled by the FDA in 2020 after studies showed that patients who used these medications were more likely to be diagnosed with cancer. Researchers found that Zantac and ranitidine users face an increased risk of developing cancer because they were contaminated with a carcinogenic chemical called NDMA. (more…)
Two new studies published by the online pharmacy Valisure have confirmed that patients who use the heartburn drug Zantac and its generic equivalent, ranitidine, face an increased risk of developing cancer. The increased risk is due to a carcinogenic chemical that forms in patients stomachs when Zantac or ranitidine are ingested. Both heartburn medications were recalled in 2019 after Valisure alerted the public that patients who used the drugs were at risk of developing cancer due to their chemical contamination. (more…)
A lawsuit recently filed against the manufacturer of Zantac alleges that drugmakers have known for decades about the risk that the heartburn medication could become contaminated with a chemical that can lead to cancer. Both Zantac and its generic equivalent, ranitidine, were recalled by the FDA in April 2020 after researchers discovered that they were contaminated with the cancer-causing chemical NDMA. (more…)
Hundreds of lawsuits have been filed so far by patients who were diagnosed with cancer after using the heartburn drugs Zantac or ranitidine. Both of these drugs were recalled in 2019 after studies linked them to an increased cancer risk. Dspite of the high number of ranitidine and Zantac lawsuits filed so far, legal experts predict that manufacturers may be facing thousands of additional lawsuits as more patients who used these drugs are diagnosed with cancer. (more…)
In 2019, the Food and Drug Administration warned that the heartburn drugs Zantac and ranitidine were contaminated with a chemical that could increase the risk of cancer for patients who used these medications. Following the FDA warning, Zantac and ranitidine were recalled by pharmaceutical companies who manufactured these drugs and pharmacies where they were sold. (more…)
The Food and Drug Administration recently published guidance for drugmakers on how to limit the amount of cancer-causing chemicals known as nitrosamines in medications. The FDA’s new guidelines were issued in response to the widespread contamination of the heartburn drug Zantac (ranitidine) with N-nitrosodimethylamine (NDMA), a type of nitrosamine. (more…)
The manufacturers of Zantac (ranitidine) are facing a Justice Department probe over allegations they failed to disclose the heartburn drug was contaminated with the cancer-causing chemical NDMA. Sanofi and GlaxoSmithKline, the two manufactures of Zantac, also face hundreds of lawsuits filed by patients diagnosed with cancer after using the drug or its generic equivalent, ranitidine. (more…)
In 2019, the heartburn medications Zantac and ranitidine were recalled and studies showed that they were contaminated with a chemical that could increase the cancer risk of patients who were treated with these drugs. Consumers who used Zantac or ranitidine and were diagnosed with cancer may qualify to file a lawsuit and receive compensation for their injuries. (more…)
